{"id":7863,"date":"2011-04-15T10:02:07","date_gmt":"2011-04-15T14:02:07","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=7863"},"modified":"2011-07-19T17:44:27","modified_gmt":"2011-07-19T21:44:27","slug":"fda-offers-cautious-support-for-olmesartan-benicar","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/04\/15\/fda-offers-cautious-support-for-olmesartan-benicar\/","title":{"rendered":"FDA Offers Cautious Support for Olmesartan (Benicar)"},"content":{"rendered":"<p><a href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm251268.htm\">The FDA announced on Thursday<\/a> that it had reviewed the results of the  ROADMAP and ORIENT trials and had determined that the benefits of  olmesartan (Benicar, Daiichi Sankyo) &#8220;continue to outweigh its potential  risks&#8221; when used as indicated for the treatment of high blood pressure. <a href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm215222.htm\"> In June 2010 the FDA had announced<\/a> that it was conducting a safety  review of the drug based on the unexpected finding of a greater number  of deaths from cardiovascular causes associated with olmesartan in the  two trials.<\/p>\n<p>The FDA also said that it was working with Daiichi  Sankyo to perform additional studies and conduct additional analyses of  completed studies &#8220;to obtain more complete information about the  cardiovascular risks or benefits&#8221; of the drug.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA announced on Thursday that it had reviewed the results of the ROADMAP and ORIENT trials and had determined that the benefits of olmesartan (Benicar, Daiichi Sankyo) &#8220;continue to outweigh its potential risks&#8221; when used as indicated for the treatment of high blood pressure. In June 2010 the FDA had announced that it was [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[731,417],"class_list":["post-7863","post","type-post","status-publish","format-standard","hentry","category-general","tag-olmesartan","tag-safety-review"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=7863"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7863\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=7863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=7863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=7863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}